We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+8.7%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$19M
Cap. Flow
+$15.2M
Cap. Flow %
8.16%
Top 10 Hldgs %
49.27%
Holding
34
New
9
Increased
10
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.05M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.51M
3
RVMD icon
Revolution Medicines
RVMD
+$7.12M
4
ELVN icon
Enliven Therapeutics
ELVN
+$5.44M
5
CLYM
Climb Bio
CLYM
+$5.16M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$11.7M
2
LEGN icon
Legend Biotech
LEGN
+$8.64M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$7.39M
4
GERN icon
Geron
GERN
+$6.39M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.05M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$11M 5.89%
150,833
+21,833
+17% +$1.61M
TARS icon
2
Tarsus Pharmaceuticals
TARS
$2.61B
$10.6M 5.67%
+321,898
New +$9.05M
MRUS
3
DELISTED
Merus
MRUS
$10.4M 5.57%
208,244
+33,400
+19% +$1.74M
CGON icon
4
CG Oncology
CGON
$6.34B
$9.93M 5.32%
263,266
+88,390
+51% +$3.1M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$9.81M 5.25%
106,080
+30,442
+40% +$3.02M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.82B
$8.99M 4.81%
72,000
-1,500
-2% -$207K
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.6B
$8.34M 4.46%
211,791
+42,422
+25% +$1.71M
LBPH
8
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$8.03M 4.3%
240,892
+21,911
+10% +$754K
JSPR icon
9
Jasper Therapeutics
JSPR
$29.4M
$7.51M 4.02%
399,466
+180,852
+83% +$3.6M
RVMD icon
10
Revolution Medicines
RVMD
$39.6B
$7.41M 3.97%
+163,500
New +$7.12M
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
$7.3M 3.91%
+227,700
New +$8.51M
TYRA icon
12
Tyra Biosciences
TYRA
$1.91B
$6.35M 3.4%
270,075
+5,415
+2% +$114K
CLYM
13
Climb Bio
CLYM
$727M
$6.26M 3.35%
1,229,292
+729,292
+146% +$5.16M
GERN icon
14
Geron
GERN
$924M
$6.04M 3.23%
1,331,053
-1,405,610
-51% -$6.39M
ELVN icon
15
Enliven Therapeutics
ELVN
$3.8B
$6M 3.21%
+234,856
New +$5.44M
KURA icon
16
Kura Oncology
KURA
$964M
$5.75M 3.08%
294,081
-12,681
-4% -$257K
APLT
17
DELISTED
Applied Therapeutics
APLT
$5.26M 2.81%
+618,332
New +$3.64M
EWTX icon
18
Edgewise Therapeutics
EWTX
$4.28B
$5.01M 2.68%
+187,695
New +$3.73M
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
$4.95M 2.65%
+309,614
New +$3.79M
JANX icon
20
Janux Therapeutics
JANX
$992M
$4.94M 2.65%
+108,811
New +$4.73M
IRON icon
21
Disc Medicine
IRON
$2.91B
$4.91M 2.63%
100,000
-66,500
-40% -$3.12M
CATX icon
22
Perspective Therapeutics
CATX
$341M
$4.56M 2.44%
341,739
-54,503
-14% -$725K
DFTX
23
Definium Therapeutics
DFTX
$5.88B
$4.49M 2.4%
788,508
-176,918
-18% -$1.23M
ALMS
24
Alumis Inc
ALMS
$3.65B
$4.47M 2.39%
418,416
-200,334
-32% -$2.43M
RLAY icon
25
Relay Therapeutics
RLAY
$4.34B
$4.43M 2.37%
+626,058
New +$4.68M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q3 2024 Portfolio in Review

As of Q3 2024, Ally Bridge Group held 34 positions worth $187M, up 11% from $168M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Ally Bridge Group deployed $15.2M of net new capital in Q3 2024, opening 9 new positions and adding to 10 existing holdings. Its largest new stake was Tarsus Pharmaceuticals: 321,898 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Geron, an estimated $6.39M trimmed.

  • Ally Bridge Group's largest Q3 2024 buy was Tarsus Pharmaceuticals: 321,898 shares worth $10.6M.
  • Ally Bridge Group added most to Climb Bio in Q3 2024, an estimated $5.16M increase.
  • Ally Bridge Group's biggest Q3 2024 reduction was Geron, cutting an estimated $6.39M.
  • Ally Bridge Group fully exited Soleno Therapeutics in Q3 2024, selling an estimated $11.7M.
  • Ally Bridge Group's ten largest holdings make up 49% of its $187M portfolio in Q3 2024.
  • Ally Bridge Group opened 9 new positions and closed 5 in Q3 2024.
  • Ally Bridge Group's portfolio value rose 11% quarter-over-quarter to $187M.

Based on Ally Bridge Group's 13F filing for Q3 2024, filed 14 Nov 2024.